Last reviewed · How we verify
EC Aspirin
At a glance
| Generic name | EC Aspirin |
|---|---|
| Also known as | Acetylsalicylic Acid, ASA, Aspergum, aspirin, Ecotrin |
| Sponsor | Roswell Park Cancer Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease (PHASE4)
- Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes (EARLY_PHASE1)
- Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II (PHASE1)
- Aspirin Resistance in Trinidad. (PHASE2)
- Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery (PHASE2)
- Aspirin for Postpartum Patients With Preeclampsia (PHASE2)
- Postpartum ASA and NT-proBNP (PHASE4)
- Anti-Platelets in Chronic Obstructive Pulmonary Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EC Aspirin CI brief — competitive landscape report
- EC Aspirin updates RSS · CI watch RSS
- Roswell Park Cancer Institute portfolio CI